Trial Profile
Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Nov 2015
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Biomarker; Pharmacodynamics
- 27 Nov 2015 New trial record